Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases
Clinical trial NCT07161193 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07161193
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-09-30
- Primary completion
- 2027-08-18
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.